Production of first generation adenoviral vectors for preclinical protocols: Amplification, purification and functional titration

Journal of Bioscience and Bioengineering

Volumn 112, Issue 5, 2011, Pages 415-421

  Armendáriz Borunda, Juan ^a,b   Bastidas Ramírez, Blanca Estela ^a   Sandoval Rodríguez, Ana ^a   González Cuevas, Jaime ^a   Gómez Meda, Belinda ^a   García Bañuelos, Jesús ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Adenovirus production; Amplification; Gene therapy; Purification; Titration; Viral vectors

Indexed keywords

ADENOVIRAL VECTORS; CRITICAL VARIABLES; HEK293 CELLS; IN-VIVO; PROTOCOL PERFORMANCE; SPECTROPHOTOMETRIC TITRATIONS; STANDARD OPERATING PROCEDURES; VIRAL PARTICLES; VIRAL VECTORS;

AMPLIFICATION; CELL CULTURE; DISEASE CONTROL; GENE TRANSFER; PURIFICATION; TITRATION; VECTORS;

GENE THERAPY;

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; CESIUM CHLORIDE; GREEN FLUORESCENT PROTEIN; NEUTROPHIL COLLAGENASE; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEK293; CLINICAL PROTOCOL; CONTROLLED STUDY; COST; EMBRYO; GENE AMPLIFICATION; GENE THERAPY; HUMAN; HUMAN CELL; ILIAC VEIN; IN VIVO STUDY; INFECTION; LIVER FIBROSIS; MALE; NONHUMAN; PURIFICATION; RAT; SPECTROPHOTOMETRY; TITRIMETRY; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; CELL LINE; CENTRIFUGATION, DENSITY GRADIENT; CESIUM; CHLORIDES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; MALE; RATS; SPECTROPHOTOMETRY;

ADENOVIRIDAE; RATTUS;

EID: 81255160721     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2011.07.018     Document Type: Article

References (43)

1. McConnell M.J., Imperiale M.J. Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther. 2004, 15:1022-1033.
2. Park M.T., Lee M.S., Kim S.H., Jo E.C., Lee G.M. Influence of culture passages on growth kinetics and adenovirus vector production for gene therapy in monolayer and suspension cultures of HEK 293 cells. Appl. Microbiol. Biotechnol. 2004, 65:553-558.
3. Volpers C., Kochanek S. Adenoviral vectors for gene transfer and therapy. J. Gene Med. 2004, 6:S164-S171.
4. George J.A. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 2003, 10:1135-1141.
5. Wang M., Zheng X., Xiao-Mei R., Hao H.D., McMasters M.K., Zhou H.S. Adenoviral vector systems for gene therapy. Gene Ther. Mol. Biol. 2005, 9:291-300.
6. Anja E., Xu H., Kay M.A. Episomal persistence of recombinant adenoviral vector genomes during the cell cycle in vivo. J. Virol. 2003, 77:7689-7695.
7. Kim J., Lee S., Cho Y., Park K., Kim Y., Lee J.H. Development of a packaging cell line for propagation of replication-deficient adenovirus vector. Exp. Mol. Med. 2001, 33:145-149.
8. Chi-Hsien L., Pel-Shan W. Optimization of adenoviral production in human embryonic kidney cells using response surface methodology. J. Biosci. Bioeng. 2007, 103:406-411.
9. Trapnell B.C. Adenoviral vectors for gene transfer. Adv. Drug Deliv. Rev. 1993, 12:185-199.
10. Vorburger S.A., Hunt K.K. Adenoviral gene therapy. Oncologist 2002, 7:46-59.
11. Russell W.C. Adenoviruses: update on structure and function. J. Gen. Virol. 2009, 90:1-20.
12. Shabram P., Aguilar-Cordova E. Multiplicity of infection/multiplicity of confusion. Mol. Ther. 2000, 2:420-421.
13. Lowenstein P.R., Castro M.G. Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: peculiarities, mechanisms, and consequences. Gene Ther. 2003, 10:946-954.
14. Ugai H., Watanabe S., Suzuki E., Tsutsui-Nakata H., Yokoyama K.K., Murata T. Stability of a recombinant adenoviral vector: optimization of conditions for storage, transport and delivery. Jpn. J. Cancer Res. 2002, 93:598-603.
15. Ferreira T.B., Carrondo M.J.T., Alves P.M. Effect of ammonia production on intracellular pH: consequent effect on adenovirus vector production. J. Biotechnol. 2007, 129:433-438.
16. Nyberg-Hoffman C., Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies. Nat. Med. 1999, 5:955-957.
17. Russell W.C. Update on adenovirus and its vectors. J. Gen. Virol. 2000, 81:2573-2604.
18. Kamen A., Henry O. Development and optimization of an adenovirus production process. J. Gene Med. 2004, 6:S184-S192.
19. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36:59-74.
20. Danthinne X., Imperiale M.J. Production of first generation adenovirus vectors: a review. Gene Ther. 2000, 7:1707-1714.
21. Nadeau I., Kamen A. Production of adenovirus vector for gene therapy. Biotechnol. Adv. 2003, 20:475-489.
22. Yamada K., Morishita N., Katsuda T., Kubo S., Gotoh A., Yamaji H. Adenovirus vector production using low-multiplicity infection of 293 cells. Cytotechnology 2009, 5:153-160.
23. Nyberg-Hoffman C., Shabram P., Li W., Giroux D., Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 1997, 3:808-811.
24. Tsien R.Y. The green fluorescent protein. Annu. Rev. Biochem. 1998, 67:509-544.
25. Weiss D.J., Liggitt D., Clark J.G. In situ histochemical detection of β-galactosidase activity in lung: assessment of X-gal reagent in distinguishing lacZ gene expression and endogenus β-galactosidase activity. Hum. Gene Ther. 1997, 8:1545-1554.
26. Salgado S., García J., Vera J., Siller F., Bueno M., Miranda A., Segura A., Grijalva G., Segura J., Orozco H., Hernández-Pando R., Fafutis M., Aguilar L.K., Aguilar-Cordova E., Armendariz-Borunda J. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther. 2000, 2:545-551.
27. Siller-López F., Sandoval A., Salgado S., Salazar A., Bueno M., Garcia J., Vera J., Gálvez J., Hernández I., Ramos M., Aguilar-Cordova E., Armendariz-Borunda J. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004, 126:1122-1133.
28. Garcia-Bañuelos J., Siller-Lopez F., Miranda A., Aguilar L.K., Aguilar-Cordova E., Armendariz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther. 2002, 9:127-134.
29. Di Paolo N.C., Shayakhmetov D.M. Adenovirus de-targeting from the liver. Curr. Opin. Mol. Ther. 2009, 11:523-531.
30. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus. 1. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36:115-125.
31. López-De León A., Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 1995, 33:737-743.
32. Reeves L., Cornetta K. Clinical retroviral vector production: step filtration using clinically approved filters improves titers. Gene Ther. 2000, 7:1993-1998.
33. Toietta G., Pastore L., Cerullo V., Finegold M., Beaudet A.L., Lee B. Generation of helper-dependent adenoviral vectors by homologous recombination. Mol. Ther. 2002, 5:204-210.
34. Gerin P.A., Searle P.F., Al-Rubeai M. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol. Prog. 1999, 15:941-948.
35. Merten O.W., Geny-Fiamma C., Douar A.M. Current issues in adeno-associated viral vector production. Gene Ther. 2005, 12:S51-S61.
36. Hildinger M., Baldi L., Stettler M., Wurm F.M. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol. Lett. 2007, 29:1713-1721.
37. Bett A.J., Prevec L., Graham F.I. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 1993, 67:5911-5921.
38. Kennedy M.A., Parks R.J. Adenovirus virion stability and the viral genome: size matters. Mol. Ther. 2009, 17:1664-1666.
39. Duffy A.M., O'Doherty A.M., O'Brien T., Strappe P.M. Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional technique. Gene Ther. 2005, 12:S62-S72.
40. Tollefson A.E., Kuppuswamy M., Shashkova E.V., Doronin K., Wold W.S. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol. Med. 2007, 130:223-235.
41. Peng H.H., Wu S., Davis J.J., Wang L., Roth J.A., Marini F.C., Fang B. A rapid and efficient method for purification of recombinant adenovirus with RGD-modified fibers. Anal. Biochem. 2006, 354:140-147.
42. U.S.Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research Guidance for industry: guidance for human somatic cell therapy and gene therapy. Hum. Gene Ther. 2001, 12:303-314.
43. Hutchins H., Sajjadi N., Seaver S., AShepherd A., Bauer S., Simek S., Carson K., Aguilar-Cordova E. Working toward an adenoviral vector testing standard. Mol. Ther. 2000, 2:532-534.